Compared side by side

Retatrutide vs VK2735: how they differ

Reviewed How we check the libraryPublished by PepVault

The short answer

VK2735 switches on two receptors, GLP-1 and GIP, the pair tirzepatide works through; retatrutide adds a third, glucagon, whose arm adds calorie burn (shown in mice). Neither is approved: both are weekly shots in phase 3, and VK2735 is also being tested as a daily tablet. Retatrutide’s top dose averaged about 25–28% weight loss at 80 weeks in phase 3, and VK2735 took off about 9% to 15% in its 13-week phase 2 trial.

Side by side

ComparedRetatrutideVK2735
CategoryMetabolic & GLP-1Metabolic & GLP-1
Also known asLY3437943VK-2735, VK 2735
What it isThe first triple agonist to reach phase 3: it activates GLP-1, GIP and glucagon receptors at once, and the glucagon arm adds extra calorie burn (shown in mice).A weekly GLP-1 and GIP dual agonist from Viking Therapeutics, the same two-receptor approach as tirzepatide, also being tested as a daily tablet.
How it worksTriple GIP/GLP-1/glucagon receptor agonist. Produces large weight loss through appetite suppression and improved metabolic function; the glucagon arm adds energy expenditure, shown so far in mice. Its trials step the dose up every 4 weeks because GI side effects rise with the dose; in phase 2 they were milder with a 2 mg start than a 4 mg one.Once-weekly peptide that switches on both the GLP-1 and the GIP receptors, the same pair tirzepatide works through. A side chain stretches its half-life to about 7 to 10 days in people, long enough for weekly shots. The idea is the one tirzepatide proved: two incretin signals that curb appetite and food intake together. Viking also makes it as a daily tablet, the same molecule by mouth. Investigational, in phase 3 since June 2025.
Commonly reportedAppetite suppression even stronger than tirzepatide, GI side effects after each step-up, and a higher resting heart rate. Its top dose averaged about 25–28% weight loss at 80 weeks in phase 3; it isn't approved yet.In trials, nausea and other GI effects early on, fading as the dose holds. It is in phase 3 and not approved anywhere.
Studied rangeResearch range: 1–12 mg, starting dose 2 mg. Studied in research — not a recommendation.Research range: 2.5–17.5 mg, starting dose 2.5 mg. Studied in research — not a recommendation.
How oftenWeeklyWeekly
Half-life~6 days (measured in early trials in people)~9 days (measured in people: 170–250 hours after single doses, Viking phase 1, 2023)
RouteSubQ injectionSubQ injection
Typical runPhase 3 trials use continuous dosing. Community mirrors this — long-term with slow titration.Used continuously, once weekly, in its trials: 13 weeks in phase 2 and 78 weeks in phase 3. In Viking's maintenance study, people who switched after 21 weekly doses to a shot every other week or once a month kept most of their loss over the next 12 weeks; on placebo they kept about 61%.
EvidenceEstablished: clinical trials or FDA-approved use existsModerate: animal studies + some human data
Common side effectsNausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, abdominal painNausea, constipation, diarrhea, vomiting, acid reflux, fatigue, dry mouth

Typical run: Community practice — opinions vary. Not a clinical recommendation.

A smiling man in a grey t-shirt in his living room, holding his phone

Model. Individual results vary.

PepVault for iPhone

Taking retatrutide or VK2735? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

Retatrutide

  • Day 1–28 · 2 mg Triple-agonist is kicking in
  • Day 29–84 · 4 mg Dose-response steepens
  • Day 60+ · 9 mg Watch for dysesthesia at higher doses
  • Day 84+ This is a maintenance medication, not a course
  • Day 85–168 · 8 mg Higher steps: strong satiety
  • Day 169–336 No plateau yet at week 48
  • Day 337–476 Phase 3 territory: the headline numbers

Every card for retatrutide, with its sources

VK2735

  • Day 1–21 · 2.5 mg Low start, first weeks
  • Day 22–91 The first 13 weeks
  • Day 22–546 · 7.5 mg The lowest phase 3 dose
  • Day 43–546 · 12.5 mg The middle phase 3 dose
  • Day 43–546 · 17.5 mg The top phase 3 dose
  • Day 150+ Holding the loss on fewer shots

Every card for VK2735, with its sources

Questions people ask

How long do retatrutide and VK2735 last?

The half-life of retatrutide is ~6 days (measured in early trials in people). The half-life of VK2735 is ~9 days (measured in people: 170–250 hours after single doses, Viking phase 1, 2023).

How often are retatrutide and VK2735 taken?

Retatrutide: weekly. Route: SubQ injection. VK2735: weekly. Route: SubQ injection.

How are retatrutide and VK2735 dosed in research?

The research range for retatrutide is 1–12 mg, with a 2 mg starting dose. The research range for VK2735 is 2.5–17.5 mg, with a 2.5 mg starting dose. Studied in research — not a recommendation.

What are the common side effects of retatrutide and VK2735?

For retatrutide, the library lists: nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, abdominal pain. For VK2735: nausea, constipation, diarrhea, vomiting, acid reflux, fatigue, dry mouth.

Each one in full

Track it in the app

PepVault for iPhone

Taking retatrutide or VK2735? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo